m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05210
|
[1] | |||
Non-coding RNA
LRRC75A-AS1
IGF2BP1
lncRNA miRNA circRNA
Direct
Inhibition
m6A modification
SYVN1
SYVN1
IGF2BP1
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) | READER | |||
| m6A Target | E3 ubiquitin-protein ligase synoviolin (SYVN1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Small nucleolar RNA host gene 29 (SNHG29) | LncRNA | View Details | ||
| Regulated Target | Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) | View Details | |||
| Crosstalk Relationship | ncRNA → m6A | Inhibition | |||
| Crosstalk Mechanism | ncRNAs directly impacts m6A modification through recruiting m6A regulator | ||||
| Crosstalk Summary | SNHG29 competitively binds to IGF2BP1 protein to destabilize E3 ubiquitin-protein ligase synoviolin (SYVN1) mRNA, subsequently suppresses SYVN1-mediated NLRP3 ubiquitination degradation and activates IL1beta/Smad2/3 signaling, thus promoting EMT in cervical cancer. Implication: LRRC75A-AS1 promotes cervical cancer progression, and this study suggests LRRC75A-AS1 as a new therapeutic target for cervical cancer. | ||||
| Responsed Disease | Cervical cancer | ICD-11: 2C77 | |||
In-vitro Model |
C-33 A | Cervical squamous cell carcinoma | Homo sapiens | CVCL_1094 | |
| HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | ||
| SiHa | Cervical squamous cell carcinoma | Homo sapiens | CVCL_0032 | ||
| Ca Ski | Cervical squamous cell carcinoma | Homo sapiens | CVCL_1100 | ||
| ME-180 | Human papillomavirus-related cervical squamous cell carcinoma | Homo sapiens | CVCL_1401 | ||
| In-vivo Model | Mice were blindly grouped into sh-NC, sh-LRRC75A-AS1, OE-NC, and OE-LRRC75A-AS1 groups (n = 7 per group). sh-NC or sh-LRRC75A-AS1-transfected HeLa cells and OE-NC or OE-LRRC75A-AS1-transfected CaSki cells were subcutaneously injected into the right flank (1 × 106 cells in 200 μ L PBS/mouse). | ||||